- ISIN
- US52635N1037
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 25, 2021
Highlights
- Market Cap
- $219.78M
- Enterprise Value
- $195.25M
- EPS (TTM)
- -$3.66
- Total Revenue (TTM)
- $20.99M
- Gross Profit (TTM)
- $19.37M
- EBITDA (TTM)
- -$116.01M
- Year Range
- $6.61 - $50.40
- Target Price
- $51.67
- ROA (TTM)
- -39.99%
- ROE (TTM)
- -44.22%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LENZ Performance Chart
LENZ Therapeutics Inc (LENZ) is down 56.2% since the beginning of the year. At $7 per share, LENZ is trading 86.1% below its 52-week high of $50.
Loading charts...
Returns By Period
LENZ Therapeutics Inc (LENZ) has returned -56.19% so far this year and -76.45% over the past 12 months.
LENZ Therapeutics Inc
- 1D
- -1.68%
- 1M
- -24.46%
- YTD
- -56.19%
- 6M
- -74.96%
- 1Y
- -76.45%
- 3Y*
- -10.86%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
LENZ Monthly Returns History
Based on dividend-adjusted daily data since Jun 25, 2021, LENZ's average daily return is -0.05%, while the average monthly return is -0.46%.
Historically, 46% of months were positive and 54% were negative. The best month was Mar 2024 with a return of +97.7%, while the worst month was Dec 2025 at -47.6%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.
On a daily basis, LENZ closed higher 48% of trading days. The best single day was Mar 15, 2024 with a return of +36.3%, while the worst single day was Jan 6, 2023 at -39.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.13% | -14.73% | -32.17% | -1.86% | -13.36% | -9.90% | -56.19% | ||||||
| 2025 | -11.57% | -14.49% | 17.77% | 10.91% | 2.40% | 0.38% | 1.57% | 29.76% | 20.58% | -36.20% | 2.69% | -47.58% | -44.58% |
| 2024 | 3.82% | 24.63% | 97.69% | -28.93% | -3.65% | 13.08% | 43.61% | -5.80% | 1.50% | 13.56% | 32.05% | -18.90% | 230.71% |
| 2023 | -35.24% | 22.33% | -6.84% | 30.20% | -10.97% | -8.45% | -2.69% | -12.25% | 11.71% | 0.40% | -8.84% | 15.42% | -21.08% |
| 2022 | -24.86% | -1.50% | -44.57% | -21.18% | -41.54% | 17.02% | 14.55% | 5.08% | -4.23% | 10.73% | 0.57% | -5.95% | -73.29% |
| 2021 | 66.11% | -30.49% | -8.52% | -16.12% | -22.27% | -29.20% | 37.80% | -32.81% |
Benchmark Metrics
LENZ Therapeutics Inc has an annualized alpha of -26.75%, beta of 1.34, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since June 28, 2021.
- This stock participated in 195.84% of S&P 500 Index downside but only 11.92% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -26.75%
- Beta
- 1.34
- R²
- 0.09
- Upside Capture
- 11.92%
- Downside Capture
- 195.84%
Return for Risk
Risk / Return Rank
LENZ ranks 6 for risk / return — in the bottom 6% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for LENZ Therapeutics Inc (LENZ) and compare them to S&P 500 Index.
| LENZ | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.18 | ||
| Sortino ratioReturn per unit of downside risk | -4.77 | ||
| Omega ratioGain probability vs. loss probability | 0.79 | 1.41 | -0.62 |
| Calmar ratioReturn relative to maximum drawdown | -0.89 | 2.93 | -3.81 |
| Martin ratioReturn relative to average drawdown | -1.41 | 13.52 | -14.93 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
LENZ Therapeutics Inc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 |
|---|---|---|---|
| Dividend | $0.00 | $0.00 | $8.24 |
Dividend yield | 0.00% | 0.00% | 28.54% |
Monthly Dividends
The table displays the monthly dividend distributions for LENZ Therapeutics Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $8.24 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $8.24 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the LENZ Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the LENZ Therapeutics Inc was 93.98%, occurring on Jan 6, 2023. The portfolio has not yet recovered.
The current LENZ Therapeutics Inc drawdown is 93.15%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -93.98%Jan 2023 | 1y 6mo | — | 4y 11moJul 2021 - now |
Drawdown Indicators
| LENZ | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.98% | -56.78% | -37.20% |
Max Drawdown (1Y)Largest decline over 1 year | -86.44% | -9.10% | -77.34% |
Max Drawdown (3Y)Largest decline over 3 years | -86.44% | -18.90% | -67.54% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -93.15% | -0.74% | -92.41% |
Average DrawdownAverage peak-to-trough decline | -78.62% | -10.72% | -67.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 54.23% | 1.97% | +52.26% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of LENZ Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how LENZ Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LENZ relative to other companies in the Biotechnology industry. Currently, LENZ has a P/S ratio of 9.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LENZ in comparison with other companies in the Biotechnology industry. Currently, LENZ has a P/B value of 0.9. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LENZ
Add LENZ Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LENZ